CEL-SCI (CVM +3.1%) is up on below-average volume in response to data on a new potential rheumatoid arthritis (RA) vaccine candidate called DerG-PG275Cit that it says can complement its existing RA vaccine CEL-4000. The results were presented at i-Chem2019 in San Francisco.
In a mouse model of RA, vaccination with DerG LEAPS conjugates, alone or together with CEL-4000, modulated the inflammatory response and stopped the progression of arthritis.
The company and collaborators are leveraging the former’s LEAPS platform technology to develop a therapeutic antigen-specific treatment for RA under a $1.5M grant from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases.
After the preclinical and IND-enabling studies have been completed, CEL-SCI plans to file an IND with the FDA seeking signoff to start clinical trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.